By Gary M. White, MD
Note the diffuse, non-scarring hair loss.
Anagen effluvium (AE) is the name for the common occurrence of hair loss during chemotherapy.
Hair loss is diffuse and non-scarring. It begins approximately 1-2 months after beginning chemotherapy. Around 10% of hairs are unaffected initially as that percentage are in a resting phase. If the chemotherapy is prolonged, total hair loss may follow. Alopecia is more common and more severe with combination chemotherapy.
The use of thiotepa is associated with permanent hair loss (J Am Acad Dermatol 2014;70:499-505).
In most cases, the hair regrows after cessation of the chemotherapy. Rare cases, however, have been reported in which the hair did not regrow. Sometimes, the hair may regrow with a different color and curl.
In terms of prevention, a cooling cap has been shown to be quite helpful. One system features a “cold cap” that is fitted to a patient’s head during chemotherapy. Cooling is done 30 minutes before, during, and for 90 minutes after chemotherapy sessions. In the Scalp Cooling Alopecia Prevention (SCALP) Trial, about half of treated patients retained their hair, compared with none of the untreated patients.
Woman with breast cancer (scar visible) followed by chemotherapy including docetaxel which has caused both a photo recall dermatitis and anagen effluvium.
Homepage | FAQs | Use of Images | Contact Dr. White